SUBSCRIBE

Breaking News on Contract Research, Manufacturing & Clinical Trials

News in brief

Beta Pharma lands cancer drug manufacturing and development contract

25-Jul-2012
Last updated on 25-Jul-2012 at 14:31 GMT

Beta Pharma Canada will produce a batch of adva-27a, a developmental cancer drug being developed by Sunshine Biopharma.

Adva-27a is an anti-cancer compound which has demonstrated the ability to kill resistant breast cancer cells (MCF-7/MDR) and small-cell lung cancer cells (H69AR) in preclinical studies conducted to date.

Montreal-based Beta Pharma Canada - an affiliate of Beta Pharma with offices and facilities in Connecticut (USA) and Shanghai (China) – will also provide synthesis parameters for future scale-up and large scale manufacturing of the drug.

Sunshine CEO Steve Slilaty said: “We are delighted to be working with Beta Pharma Canada with excellent in-house synthesis capability and can amass additional resources through its corporate affiliations” adding that “We anticipate delivery of the new batch of Adva-27a together with the synthesis parameters by the end of the month.”

Subscribe to our FREE newsletter

Get FREE access to authoritative breaking news, videos, podcasts, webinars and white papers. SUBSCRIBE

Key Industry Events

 

Access all events listing

Our events, Events from partners...

On demand Supplier Webinars

A brief history of bioavailability
William Reed Business Media
Bioavailability market dynamics
William Reed Business Media
All supplier webinars